相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
Ashkan Emadi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
Maria Paola Martelli et al.
BLOOD (2015)
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells
Hiba El Hajj et al.
BLOOD (2015)
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Alan K. Burnett et al.
BLOOD (2015)
DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia
Alison R. Sehgal et al.
CLINICAL CANCER RESEARCH (2015)
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Naveen Pemmaraju et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Peter Paschka et al.
HAEMATOLOGICA (2015)
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel et al.
HAEMATOLOGICA (2015)
The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
E. J. Duncavage et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial
Christoph Roellig et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prognostic Significance of NPM1 Mutations in the Absence of FLT3-Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
Fabiana Ostronoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology
Young-Uk Cho et al.
LEUKEMIA & LYMPHOMA (2015)
WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation
Yiping Wang et al.
MOLECULAR CELL (2015)
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
H-A Hou et al.
BLOOD CANCER JOURNAL (2015)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Peter Paschka et al.
HAEMATOLOGICA (2015)
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel et al.
HAEMATOLOGICA (2015)
Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition
Subarna Sinha et al.
BLOOD (2015)
Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations
Robert S. Ohgami et al.
MODERN PATHOLOGY (2015)
Specific macrothrombocytopenia/hemolytic anemia associated with sitosterolemia
Zhaoyue Wang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Hartmut Doehner et al.
BLOOD (2014)
BRD4 A BET(ter) target for the treatment of AML?
Peter Valent et al.
CELL CYCLE (2014)
Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
Douglas B. Johnson et al.
CLINICAL CANCER RESEARCH (2014)
IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation
Shunichiro Yamaguchi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring
Rajyalakshmi Luthra et al.
HAEMATOLOGICA (2014)
Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis
Matthias Stelljes et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Physicians' Attitudes About Multiplex Tumor Genomic Testing
Stacy W. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
Roelof Willemze et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Detection of Mutations in Myeloid Malignancies through Paired-Sample Analysis of Microdroplet-PCR Deep Sequencing Data
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
M. A. Dawson et al.
LEUKEMIA (2014)
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Sabine Kayser et al.
LEUKEMIA & LYMPHOMA (2014)
Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations
Sheng-Chieh Chou et al.
LEUKEMIA RESEARCH (2014)
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
Harry P. Erba et al.
LEUKEMIA RESEARCH (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
P. Tan et al.
BLOOD CANCER JOURNAL (2014)
DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia
Raajit Rampal et al.
CELL REPORTS (2014)
Intermediate-risk acute myeloid leukemia therapy: current and future
Konstanze Doehner et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
Yuan-Shuo Hsueh et al.
AUTOPHAGY (2013)
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
Sarah Bertoli et al.
BLOOD (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)
Verena I. Gaidzik et al.
BLOOD (2013)
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA
Richard F. Schlenk et al.
BLOOD (2013)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Outcome of older patients with acute myeloid leukemia: An Analysis of SEER Data Over 3 Decades
Mya S. Thein et al.
CANCER (2013)
Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
Stefan Groeschel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
S. Schnittger et al.
LEUKEMIA (2013)
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
David A. Macdonald et al.
LEUKEMIA & LYMPHOMA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms
Gabriela Silva et al.
PLOS ONE (2013)
EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and-7/del(7q) in De Novo Acute Myeloid Leukemia
Xiuli Wang et al.
PLOS ONE (2013)
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
Christian Posch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Antonino Grassadonia et al.
Cancers (2013)
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)
Friederike Schneider et al.
ANNALS OF HEMATOLOGY (2012)
Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPMI and CEBPA without FLT3-ITD
Gaelle Laboure et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Frank G. Rueckner et al.
BLOOD (2012)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
Ana Flavia Tiburcio Ribeiro et al.
BLOOD (2012)
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Alireza Eghtedar et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
Roland B. Walter et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Gemtuzumab Ozogamicin: Time to Resurrect?
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Salut Brunet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures
Jason H. Mendler et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting
Mariam Ibanez et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2012)
Landscape of TET2 mutations in acute myeloid leukemia
S. Weissmann et al.
LEUKEMIA (2012)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K. H. Metzeler et al.
LEUKEMIA (2012)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
R. M. Stone et al.
LEUKEMIA (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
V. Novotny-Diermayr et al.
BLOOD CANCER JOURNAL (2012)
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
Shigeki Ohtake et al.
BLOOD (2011)
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen et al.
BLOOD (2011)
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
Je-Hwan Lee et al.
BLOOD (2011)
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers
Veronika Rockova et al.
BLOOD (2011)
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H. Metzeler et al.
BLOOD (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
The clinical development of FLT3 inhibitors in acute myeloid leukemia
Steven Knapper
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial
Matthias Stelljes et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia
Hiroto Inaba et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Felicitas Thol et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Verena I. Gaidzik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Klaus H. Metzeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PHF6 mutations in adult acute myeloid leukemia
P. Van Vlierberghe et al.
LEUKEMIA (2011)
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response
J. M. Brandwein et al.
LEUKEMIA (2011)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Alan K. Burnett et al.
BLOOD (2010)
WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system
Hsin-An Hou et al.
BLOOD (2010)
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome
Annika Dufour et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
Utz Krug et al.
LANCET (2010)
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
N. Carbuccia et al.
LEUKEMIA (2010)
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
Anjali S. Advani et al.
LEUKEMIA RESEARCH (2010)
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
Mikkael A. Sekeres et al.
BLOOD (2009)
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Annelies G. Renner et al.
BLOOD (2009)
A phase 2 study of vorinostat in acute myeloid leukemia
Eric W. Schaefer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Richard F. Schlenk et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial
Patrice Chevallier et al.
LEUKEMIA RESEARCH (2009)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century
Dianne Pulte et al.
HAEMATOLOGICA (2008)
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine:: A Cancer and Leukemia Group B study
Andreas Neubauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cytogenetically Normal Acute Myeloid Leukemia
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
Florian Heidel et al.
CANCER (2007)
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E. Lancet et al.
BLOOD (2007)
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Elihu Estey et al.
BLOOD (2007)
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML
Martin Bornhaeuser et al.
BLOOD (2007)
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
Daniel C. Link et al.
BLOOD (2007)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann et al.
CLINICAL CANCER RESEARCH (2006)
The JAK2 V617F mutation in de novo acute myelogenous leukemias
JW Lee et al.
ONCOGENE (2006)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
RL Levine et al.
BLOOD (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
RF Schlenk et al.
LEUKEMIA (2004)
分享论文
